Astellas To Transfer Fuji Facilities To Nichi-Iko
This article was originally published in PharmAsia News
Executive Summary
Astellas announced it will transfer the pharmaceutical production activities at the Japan Fuji factory to Nichi-Iko. Nichi-Iko will succeed activities at the site of Astellas Pharma Tech, a subsidiary of Astellas, on April 1, 2014.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.